Chlamydia Infection Diagnostic and Therapeutic Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast upto 2023

Chlamydia is a common sexually transmitted infection caused by bacterium Chlamydia trachomatis. Chlamydia is among the most prevalent sexually transmitted disease (STDs) and according to Centers for Disease Control and Prevention (CDC), it comprises of largest proportion of all STDs reported in the United States since 1994. In 2012, a total of 1.4 million cases of Chlamydia infection were reported to CDC in 50 states and the District of Columbia. Overall the case rate among males in 2012 rose by 3.2% during 2011-2012 which is approximately half the case rate reported in females. Chlamydia infection among women is generally asymptomatic.

Download Exclusive Sample of this Report: http://bit.ly/2eeuFJU

However the disease if left untreated can develop into pelvic inflammatory disease (PID) which is a major cause of infertility, ectopic pregnancy, and chronic pelvic pain. Similar to other STDs, chlamydia infection might facilitate the transmission of human immunodeficiency virus (HIV) infection. Moreover, pregnant women infected with chlamydia can pass the infection to their infants during delivery, potentially resulting in neonatal ophthalmia and pneumonia. In Europe there are more than 250,000 new cases are reported each year and women below 24 years in Europe have highest number of infection. In 2012, National Health Service, U.K., 206,912 people were tested positive for Chlamydia in England of which 64% were below 25 years of age.

Among women, symptoms of chlamydia include abnormal vaginal discharge, painful periods and abdominal pain with fever. Additionally itching and burning around vagina and mild pain during urination. Whereas among men symptom such as cloudy discharge, painful urination, burning around genital area and swelling of testicles are commonly found. Commonly used drugs for treating chlamydia include Amoxil, Doryx, Doxycycline, Erythrocin, Floxin, Gantrisin, Trimox, Zithromax and others. Some of the emerging diagnostic techniques in global Chlamydia Infection Diagnostic and Therapeutic market comprise molecular diagnostic, immunoassays, monoclonal antibodies, flow cytometry and gel moicrodroplet based testing. Major drivers for the growth of the market include increasing collaboration agreement with distributors, manufacturers and universities pertaining to manufacturing and research activities have escalated the market in past few years. Pipelined drugs in the market include CEL-1000, Cyanovirin-N, GEN-001, acALY18 and others.

Geographically the market for chlamydia is predominated by developed regions such as the United States and Europe. Major contributors to the growth of these markets include intense research funding and government interventions for developing cheap and affordable medications for sexually transmitted diseases under Affordable CARE Act. Availability of advanced diagnostic centers, clinics and hospitals has also contributed towards the growth and development of market in past one decade.

Asia Pacific and Rest of the World market is potentially a lucrative market and has fastest growth rate as compared to other regions pertaining to increasing sexually transmitted diseases incidences and lack of appropriate diagnostic and care centers for sexually transmitted infection/ diseases especially in the under developed parts of Asia-Pacific and Rest of the World is restraining the growth of the market. Approximately 43 million new cases of chlamydia are reported in Southeast Asian region. Whereas according to the 1999 World Health Organization report prevalence rate of chlamydia in Western Pacific region ranges from 5.7% in Thailand up to 17% in India. The aforementioned data clearly depicts the latent growth potential for drug and diagnostic companies manufacturing chlamydia related products.

Browse Research Report: http://bit.ly/2ftAt1Q

Some of the key players operating in global chlamydia infection diagnostic and therapeutic market include: Abbott Laboratories, Danaher Corporation, bioMerieux, DiaSorin SpA, NANOGEN Biopharmaceutical, Siemens AG, Thermo Fisher Scientific, Novartis Diagnostics, Fujirebio Diagnostics, Inc. and others.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.